Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation

Advances in Clinical Chemistry

Volumn 77, Issue , 2016, Pages 1-75

  Frazer Abel, A ^a   Sepiashvili, L ^b   Mbughuni, M M ^b   Willrich, M A V ^b  

^a DEPARTMENT OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Acquired angioedema; Age related macular degeneration; Alternative pathway; Atypical hemolytic uremic syndrome; C3 glomerulopathies; Classical pathway; Complement deficiency; Complement dysregulation; Complement system; Complement therapeutics; Eculizumab; HCV; Hemolytic assays; Hereditary angioedema; Lectin pathway; Lupus nephritis; Paroxysmal nocturnal hemoglobinuria; Systemic lupus erythematosus; Terminal complement complex

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C5;

ANTAGONISTS AND INHIBITORS; DEFICIENCY; HUMAN; PHYSIOLOGY;

COMPLEMENT C5; COMPLEMENT SYSTEM PROTEINS; HUMANS;

EID: 85003583713     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2016.06.001     Document Type: Chapter

References (313)

1. [1] Nesargikar, P.N., Spiller, B., Chavez, R., The complement system: history, pathways, cascade and inhibitors. Eur. J. Microbiol. Immunol. (Bp) 2 (2012), 103–111.
2. [2] Kolev, M., Le Friec, G., Kemper, C., Complement—tapping into new sites and effector systems. Nat. Rev. Immunol. 14 (2014), 811–820.
3. [3] Morgan, B.P., Gasque, P., Extrahepatic complement biosynthesis: where, when and why?. Clin. Exp. Immunol. 107 (1997), 1–7.
4. [4] Li, K., Sacks, S.H., Zhou, W., The relative importance of local and systemic complement production in ischaemia, transplantation and other pathologies. Mol. Immunol. 44 (2007), 3866–3874.
5. [5] Rock, K.L., Latz, E., Ontiveros, F., Kono, H., The sterile inflammatory response. Annu. Rev. Immunol. 28 (2010), 321–342.
6. [6] Bajic, G., Degn, S.E., Thiel, S., Andersen, G.R., Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J. 34 (2015), 2735–2757.
7. [7] Merle, N.S., Church, S.E., Fremeaux-Bacchi, V., Roumenina, L.T., Complement system part I—molecular mechanisms of activation and regulation. Front. Immunol., 6, 2015, 262.
8. [8] Merle, N.S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V., Roumenina, L.T., Complement system part II: role in immunity. Front. Immunol., 6, 2015, 257.
9. [9] Ricklin, D., Hajishengallis, G., Yang, K., Lambris, J.D., Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11 (2010), 785–797.
10. [10] Szalai, A.J., Agrawal, A., Greenhough, T.J., Volanakis, J.E., C-reactive protein: structural biology and host defense function. Clin. Chem. Lab. Med. 37 (1999), 265–270.
11. [11] Ghai, R., Waters, P., Roumenina, L.T., Gadjeva, M., Kojouharova, M.S., Reid, K.B., et al. C1q and its growing family. Immunobiology 212 (2007), 253–266.
12. [12] Kang, Y.H., Tan, L.A., Carroll, M.V., Gentle, M.E., Sim, R.B., Target pattern recognition by complement proteins of the classical and alternative pathways. Adv. Exp. Med. Biol. 653 (2009), 117–128.
13. [13] Arlaud, G.J., Gaboriaud, C., Thielens, N.M., Rossi, V., Bersch, B., Hernandez, J.F., et al. Structural biology of C1: dissection of a complex molecular machinery. Immunol. Rev. 180 (2001), 136–145.
14. [14] Law, S.K., Dodds, A.W., The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci. 6 (1997), 263–274.
15. [15] Muller-Eberhard, H.J., Polley, M.J., Calcott, M.A., Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement. J. Exp. Med. 125 (1967), 359–380.
16. [16] Cortes, C., Ohtola, J.A., Saggu, G., Ferreira, V.P., Local release of properdin in the cellular microenvironment: role in pattern recognition and amplification of the alternative pathway of complement. Front. Immunol., 3, 2012, 412.
17. [17] Fearon, D.T., Austen, K.F., Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J. Exp. Med. 142 (1975), 856–863.
18. [18] Saggu, G., Cortes, C., Emch, H.N., Ramirez, G., Worth, R.G., Ferreira, V.P., Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O). J. Immunol. 190 (2013), 6457–6467.
19. [19] Aleshin, A.E., DiScipio, R.G., Stec, B., Liddington, R.C., Crystal structure of C5b-6 suggests structural basis for priming assembly of the membrane attack complex. J. Biol. Chem. 287 (2012), 19642–19652.
20. [20] Podack, E.R., Kolb, W.P., Muller-Eberhard, H.J., The C5b-6 complex: formation, isolation, and inhibition of its activity by lipoprotein and the S-protein of human serum. J. Immunol. 120 (1978), 1841–1848.
21. [21] Morgan, B.P., The membrane attack complex as an inflammatory trigger. Immunobiology 221:6 (2016), 747–751, 10.1016/j.imbio.2015.04.006 Epub 2015 Apr 30.
22. [22] Davis, A.E. 3rd., C1 inhibitor and hereditary angioneurotic edema. Annu. Rev. Immunol. 6 (1988), 595–628.
23. [23] Davis, A.E. 3rd., Mejia, P., Lu, F., Biological activities of C1 inhibitor. Mol. Immunol. 45 (2008), 4057–4063.
24. [24] Davis, A.E. 3rd., Biological effects of C1 inhibitor. Drug News Perspect. 17 (2004), 439–446.
25. [25] Zipfel, P.F., Skerka, C., FHL-1/reconectin: a human complement and immune regulator with cell-adhesive function. Immunol. Today 20 (1999), 135–140.
26. [26] Manthey, H.D., Woodruff, T.M., Taylor, S.M., Monk, P.N., Complement component 5a (C5a). Int. J. Biochem. Cell Biol. 41 (2009), 2114–2117.
27. [27] Cataland, S.R., Holers, V.M., Geyer, S., Yang, S., Wu, H.M., Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 123 (2014), 3733–3738.
28. [28] Prohaszka, Z., Varga, L., Fust, G., The use of ‘real-time’ complement analysis to differentiate atypical haemolytic uraemic syndrome from other forms of thrombotic microangiopathies. Br. J. Haematol. 158 (2012), 424–425.
29. [29] Petri, M., Systemic Lupus International Collaborating Clinic (SLICC), SLICC revision of the ACR classification criteria for SLE [abstract]. Arthritis Rheum., 60, 2009, 895.
30. [30] Mollnes, T.E., Jokiranta, T.S., Truedsson, L., Jokiranta, T.S., Truedsson, L., Nilsson, B., Rodriguez de Cordoba, S., Kirschfink, M., Complement analysis in the 21st century. Mol. Immunol. 44 (2007), 3838–3849.
31. [31] Nilsson, B., Ekdahl, K.N., Complement diagnostics: concepts, indications, and practical guidelines. Clin. Dev. Immunol., 2012, 2012, 962702.
32. [32] Richards, A., Kathryn Liszewski, M., Kavanagh, D., Fang, C.J., Moulton, E., Fremeaux-Bacchi, V., et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol. Immunol. 44 (2007), 111–122.
33. [33] Teisner, B., Brandslund, I., Grunnet, N., Hansen, L.K., Thellesen, J., Svehag, S.E., Acute complement activation during an anaphylactoid reaction to blood transfusion and the disappearance rate of C3c and C3d from the circulation. J. Clin. Lab. Immunol. 12 (1983), 63–67.
34. [34] Norda, R., Schott, U., Berseus, O., Akerblom, O., Nilsson, B., Ekdahl, K.N., et al. Complement activation products in liquid stored plasma and C3a kinetics after transfusion of autologous plasma. Vox Sang. 102 (2012), 125–133.
35. [35] Manzi, S., Rairie, J.E., Carpenter, A.B., Kelly, R.H., Jagarlapudi, S.P., Sereika, S.M., et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum. 39 (1996), 1178–1188.
36. [36] Wu, T.C., Yang, S., Haven, S., Holers, V.M., Lundberg, A.S., Wu, H., et al. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 11 (2013), 1925–1927.
37. [37] Zhang, Y., Nester, C.M., Martin, B., Skjoedt, M.O., Meyer, N.C., Shao, D., et al. Defining the complement biomarker profile of C3 glomerulopathy. Clin. J. Am. Soc. Nephrol. 9 (2014), 1876–1882.
38. [38] Bu, F., Meyer, N.C., Zhang, Y., Borsa, N.G., Thomas, C., Nester, C., et al. Soluble C5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome. Am. J. Kidney Dis. 65:6 (2015), 968–969, 10.1053/j.ajkd.2015.02.326.
39. [39] Mahler, M., van Schaarenburg, R.A., Trouw, L.A., Anti-C1q autoantibodies, novel tests, and clinical consequences. Front. Immunol., 4, 2013, 117.
40. [40] de Liso, F., Matinato, C., Novembrino, C., Radice, A., Raffiotta, F., Ronchi, M., et al. Value of a commercial kit for detecting anti-C1q autoantibodies and correlation with immunological and clinical activity of lupus nephritis. Clin. Chem. Lab. Med. 53 (2015), 1771–1777.
41. [41] Engel, R., Rensink, I., Roem, D., Brouwer, M., Kalei, A., Perry, D., et al. ELISA to measure neutralizing capacity of anti-C1-inhibitor antibodies in plasma of angioedema patients. J. Immunol. Methods 426 (2015), 114–119.
42. [42] Fremeaux-Bacchi, V., Weiss, L., Demouchy, C., May, A., Palomera, S., Kazatchkine, M.D., Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. Nephrol. Dial. Transplant. 9 (1994), 1747–1750.
43. [43] Rother, U., A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. J. Immunol. Methods 51 (1982), 101–107.
44. [44] Gewurz, A.T., Imherr, S.M., Strauss, S., Gewurz, H., Mold, C., C3 nephritic factor and hypocomplementaemia in a clinically healthy individual. Clin. Exp. Immunol. 54 (1983), 253–258.
45. [45] Tedesco, F., Tovo, P.A., Tamaro, G., Basaglia, M., Perticarari, S., Villa, M.A., Selective C3 deficiency due to C3 nephritic factor in an apparently healthy girl. Ric. Clin. Lab. 15 (1985), 323–329.
46. [46] Karstorp, A., C3 activator and hypocomplementaemia in a “healthy” woman. Br. Med. J. 1 (1976), 501–502.
47. [47] Jozsi, M., Reuter, S., Nozal, P., Lopez-Trascasa, M., Sanchez-Corral, P., Prohaszka, Z., et al. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. Immunol. Lett. 160 (2014), 163–171.
48. [48] Miller, E.C., Chase, N.M., Densen, P., Hintermeyer, M.K., Casper, J.T., Atkinson, J.P., Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited. Clin. Immunol. 145 (2012), 241–250.
49. [49] Dragon-Durey, M.A., Blanc, C., Roumenina, L.T., Poulain, N., Ngo, S., Bordereau, P., et al. Anti-factor H autoantibodies assay. Methods Mol. Biol. 1100 (2014), 249–256.
50. [50] Watson, R., Lindner, S., Bordereau, P., Hunze, E.M., Tak, F., Ngo, S., et al. Standardisation of the factor H autoantibody assay. Immunobiology 219 (2014), 9–16.
51. [51] Strobel, S., Zimmering, M., Papp, K., Prechl, J., Jozsi, M., Anti-factor B autoantibody in dense deposit disease. Mol. Immunol. 47 (2010), 1476–1483.
52. [52] Rehm, H.L., Bale, S.J., Bayrak-Toydemir, P., Berg, J.S., Brown, K.K., Deignan, J.L., et al. ACMG clinical laboratory standards for next-generation sequencing. Genet. Med. 15 (2013), 733–747.
53. [53] Stuppia, L., Antonucci, I., Palka, G., Gatta, V., Use of the MLPA assay in the molecular diagnosis of gene copy number alterations in human genetic diseases. Int. J. Mol. Sci. 13 (2012), 3245–3276.
54. [54] Wang, H., Nettleton, D., Ying, K., Copy number variation detection using next generation sequencing read counts. BMC Bioinformatics, 15, 2014, 109.
55. [55] Castellani, C.A., Melka, M.G., Wishart, A.E., Locke, M.E., Awamleh, Z., O'Reilly, R.L., et al. Biological relevance of CNV calling methods using familial relatedness including monozygotic twins. BMC Bioinformatics, 15, 2014, 114.
56. [56] Thusberg, J., Olatubosun, A., Vihinen, M., Performance of mutation pathogenicity prediction methods on missense variants. Hum. Mutat. 32 (2011), 358–368.
57. [57] Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17:5 (2015), 405–424, 10.1038/gim.2015.30.
58. [58] Bresin, E., Rurali, E., Caprioli, J., Sanchez-Corral, P., Fremeaux-Bacchi, V., Rodriguez de Cordoba, S., Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J. Am. Soc. Nephrol. 24 (2013), 475–486.
59. [59] Heurich, M., Martinez-Barricarte, R., Francis, N.J., Roberts, D.L., Rodriguez de Cordoba, S., Morgan, B.P., et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 8761–8766.
60. [60] Bygum, A., Hereditary angio-oedema in Denmark: a nationwide survey. Br. J. Dermatol. 161 (2009), 1153–1158.
61. [61] Roche, O., Blanch, A., Caballero, T., Sastre, N., Callejo, D., Lopez-Trascasa, M., Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann. Allergy Asthma Immunol. 94 (2005), 498–503.
62. [62] Bork, K., Barnstedt, S.E., Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J. Am. Dent. Assoc. 134 (2003), 1088–1094.
63. [63] Longhurst, H.J., Nzeako, U.C., Diagnosis and treatment of hereditary angio-oedema attacks. Br. J. Hosp. Med. (Lond.) 73 (2012), 148–154.
64. [64] Bork, K., Fischer, B., Dewald, G., Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am. J. Med. 114 (2003), 294–298.
65. [65] Visy, B., Fust, G., Bygum, A., Bork, K., Longhurst, H., Bucher, C., et al. Helicobacter pylori infection as a triggering factor of attacks in patients with hereditary angioedema. Helicobacter 12 (2007), 251–257.
66. [66] Agostoni, A., Cicardi, M., Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 71 (1992), 206–215.
67. [67] Bork, K., Hardt, J., Witzke, G., Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J. Allergy Clin. Immunol. 130 (2012), 692–697.
68. [68] Bork, K., Siedlecki, K., Bosch, S., Schopf, R.E., Kreuz, W., Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin. Proc. 75 (2000), 349–354.
69. [69] Landerman, N.S., Hereditary angioneurotic edema. I. Case reports and review of the literature. J. Allergy 33 (1962), 316–329.
70. [70] Cicardi, M., Bergamaschini, L., Marasini, B., Boccassini, G., Tucci, A., Agostoni, A., Hereditary angioedema: an appraisal of 104 cases. Am. J. Med. Sci. 284 (1982), 2–9.
71. [71] Ohela, K., Hereditary angioneurotic oedema in Finland. Clinical, immunological and genealogical studies. Acta Med. Scand. 201 (1977), 415–427.
72. [72] Lumry, W.R., Castaldo, A.J., Vernon, M.K., Blaustein, M.B., Wilson, D.A., Horn, P.T., The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 31 (2010), 407–414.
73. [73] Aygoren-Pursun, E., Bygum, A., Beusterien, K., Hautamaki, E., Sisic, Z., Wait, S., et al. Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe. Orphanet J. Rare Dis., 9, 2014, 99.
74. [74] Wilson, D.A., Bork, K., Shea, E.P., Rentz, A.M., Blaustein, M.B., Pullman, W.E., Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann. Allergy Asthma Immunol. 104 (2010), 314–320.
75. [75] Donaldson, V.H., Evans, R.R., A biochemical abnormality in herediatry angioneurotic edema: absence of serum inhibitor of C’ 1-esterase. Am. J. Med. 35 (1963), 37–44.
76. [76] Osler, W., Hereditary angioneurotic edema. Am. J. Med. Sci. 95 (1888), 362–367.
77. [77] Bafunno, V., Divella, C., Sessa, F., Tiscia, G.L., Castellano, G., Gesualdo, L., et al. De novo homozygous mutation of the C1 inhibitor gene in a patient with hereditary angioedema. J. Allergy Clin. Immunol. 132 (2013), 748–750 e3.
78. [78] Blanch, A., Roche, O., Urrutia, I., Gamboa, P., Fontan, G., Lopez-Trascasa, M., First case of homozygous C1 inhibitor deficiency. J. Allergy Clin. Immunol. 118 (2006), 1330–1335.
79. [79] Lopez-Lera, A., Favier, B., de la Cruz, R.M., Garrido, S., Drouet, C., Lopez-Trascasa, M., A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation. J. Allergy Clin. Immunol. 126 (2010), 1307–1310 e3.
80. [80] Carter, P.E., Duponchel, C., Tosi, M., Fothergill, J.E., Complete nucleotide sequence of the gene for human C1 inhibitor with an unusually high density of Alu elements. Eur. J. Biochem. 197 (1991), 301–308.
81. [81] Bowen, B., Hawk, J.J., Sibunka, S., Hovick, S., Weiler, J.M., A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations. Clin. Immunol. 98 (2001), 157–163.
82. [82] Tosi, M., Molecular genetics of C1 inhibitor. Immunobiology 199 (1998), 358–365.
83. [83] Pappalardo, E., Caccia, S., Suffritti, C., Tordai, A., Zingale, L.C., Cicardi, M., Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol. Immunol. 45 (2008), 3536–3544.
84. [84] Pappalardo, E., Cicardi, M., Duponchel, C., Carugati, A., Choquet, S., Agostoni, A., et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J. Allergy Clin. Immunol. 106 (2000), 1147–1154.
85. [85] Bygum, A., Fagerberg, C.R., Ponard, D., Monnier, N., Lunardi, J., Drouet, C., Mutational spectrum and phenotypes in Danish families with hereditary angioedema because of C1 inhibitor deficiency. Allergy 66 (2011), 76–84.
86. [86] Rijavec, M., Korosec, P., Silar, M., Zidarn, M., Miljkovic, J., Kosnik, M., Hereditary angioedema nationwide study in Slovenia reveals four novel mutations in SERPING1 gene. PLoS One, 8, 2013, e56712.
87. [87] Kalmar, L., Hegedus, T., Farkas, H., Nagy, M., Tordai, A., HAEdb: a novel interactive, locus-specific mutation database for the C1 inhibitor gene. Hum. Mutat. 25 (2005), 1–5.
88. [88] Bork, K., Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema. Immunotherapy 6 (2014), 533–551.
89. [89] Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., Agostoni, A., Plasma bradykinin in angio-oedema. Lancet 351 (1998), 1693–1697.
90. [90] Nussberger, J., Cugno, M., Cicardi, M., Agostoni, A., Local bradykinin generation in hereditary angioedema. J. Allergy Clin. Immunol. 104 (1999), 1321–1322.
91. [91] Rosen, F.S., Pensky, J., Donaldson, V., Charache, P., Hereditary angioneurotic edema: two genetic variants. Science 148 (1965), 957–958.
92. [92] Hack, C.E., Relan, A., van Amersfoort, E.S., Cicardi, M., Target levels of functional C1-inhibitor in hereditary angioedema. Allergy 67 (2012), 123–130.
93. [93] Bork, K., Barnstedt, S.E., Koch, P., Traupe, H., Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356 (2000), 213–217.
94. [94] Binkley, K.E., Davis, A. 3rd., Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J. Allergy Clin. Immunol. 106 (2000), 546–550.
95. [95] Bork, K., Gul, D., Hardt, J., Dewald, G., Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am. J. Med. 120 (2007), 987–992.
96. [96] Dewald, G., Bork, K., Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem. Biophys. Res. Commun. 343 (2006), 1286–1289.
97. [97] Zuraw, B.L., Bork, K., Binkley, K.E., Banerji, A., Christiansen, S.C., Castaldo, A., et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 33:Suppl. 1 (2012), S145–S156.
98. [98] Bork, K., Wulff, K., Witzke, G., Hardt, J., Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations. Allergy 70 (2015), 1004–1012.
99. [99] Jolles, S., Williams, P., Carne, E., Mian, H., Huissoon, A., Wong, G., et al. A UK national audit of hereditary and acquired angioedema. Clin. Exp. Immunol. 175 (2014), 59–67.
100. [100] Zanichelli, A., Magerl, M., Longhurst, H., Fabien, V., Maurer, M., Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy Asthma Clin. Immunol., 9, 2013, 29.
101. [101] Li, H.H., Busse, P., Lumry, W.R., Frazer-Abel, A., Levy, H., Steele, T., et al. Comparison of chromogenic and ELISA functional C1 inhibitor tests in diagnosing hereditary angioedema. J. Allergy Clin. Immunol. Pract. 3 (2015), 200–205.
102. [102] Cicardi, M., Aberer, W., Banerji, A., Bas, M., Bernstein, J.A., Bork, K., et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 69 (2014), 602–616.
103. [103] Cicardi, M., Zanichelli, A., Acquired angioedema. Allergy Asthma Clin. Immunol., 6, 2010, 14.
104. [104] Gompels, M.M., Lock, R.J., Morgan, J.E., Osborne, J., Brown, A., Virgo, P.F., A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. J. Clin. Pathol. 55 (2002), 145–147.
105. [105] Gompels, M.M., Lock, R.J., Abinun, M., Bethune, C.A., Davies, G., Grattan, C., et al. C1 inhibitor deficiency: consensus document. Clin. Exp. Immunol. 139 (2005), 379–394.
106. [106] Tarzi, M.D., Hickey, A., Forster, T., Mohammadi, M., Longhurst, H.J., An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema. Clin. Exp. Immunol. 149 (2007), 513–516.
107. [107] Karim, Y., Griffiths, H., Deacock, S., Normal complement C4 values do not exclude hereditary angioedema. J. Clin. Pathol. 57 (2004), 213–214.
108. [108] Zuraw, B.L., Sugimoto, S., Curd, J.G., The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiency. J. Allergy Clin. Immunol. 78 (1986), 1115–1120.
109. [109] Zuraw, B.L., Kalfus, I., Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am. J. Med. 125 (2012), e1–e7 938.
110. [110] Markovic, S.N., Inwards, D.J., Phyliky, R.P., Acquired C1 esterase inhibitor deficiency. Ann. Intern. Med., 133, 2000, 839.
111. [111] Caballero, T., Farkas, H., Bouillet, L., Bowen, T., Gompel, A., Fagerberg, C., et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J. Allergy Clin. Immunol. 129 (2012), 308–320.
112. [112] Johnson, C.A., Densen, P., Hurford, R.K. Jr., Colten, H.R., Wetsel, R.A., Type I human complement C2 deficiency. A 28-base pair gene deletion causes skipping of exon 6 during RNA splicing. J. Biol. Chem. 267 (1992), 9347–9353.
113. [113] Johnson, C.A., Densen, P., Wetsel, R.A., Cole, F.S., Goeken, N.E., Colten, H.R., Molecular heterogeneity of C2 deficiency. N. Engl. J. Med. 326 (1992), 871–874.
114. [114] Figueroa, J.E., Densen, P., Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4 (1991), 359–395.
115. [115] Grumach, A.S., Kirschfink, M., Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol. Immunol. 61 (2014), 110–117.
116. [116] Turner, M.W., Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol. Today 17 (1996), 532–540.
117. [117] Yang, Y., Chung, E.K., Zhou, B., Blanchong, C.A., Yu, C.Y., Fust, G., et al. Diversity in intrinsic strengths of the human complement system: serum C4 protein concentrations correlate with C4 gene size and polygenic variations, hemolytic activities, and body mass index. J. Immunol. 171 (2003), 2734–2745.
118. [118] Yu, D., Kandimalla, E.R., Cong, Y., Tang, J., Tang, J.Y., Zhao, Q., et al. Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: role of nucleosides in the flanking sequences. J. Med. Chem. 45 (2002), 4540–4548.
119. [119] Stefansson Thors, V., Kolka, R., Sigurdardottir, S.L., Edvardsson, V.O., Arason, G., Haraldsson, A., Increased frequency of C4B*Q0 alleles in patients with Henoch–Schonlein purpura. Scand. J. Immunol. 61 (2005), 274–278.
120. [120] Orbai, A.M., Truedsson, L., Sturfelt, G., Nived, O., Fang, H., Alarcon, G.S., et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus 24 (2015), 42–49.
121. [121] Schramm, E.C., Staten, N.R., Zhang, Z., Bruce, S.S., Kellner, C., Atkinson, J.P., et al. A quantitative lateral flow assay to detect complement activation in blood. Anal. Biochem. 477 (2015), 78–85.
122. [122] Sethi, S., Quint, P.S., O'Seaghdha, C.M., Fervenza, F.C., Bijol, V., Dorman, A., et al. C4 glomerulopathy: a disease entity associated with C4d deposition. Am. J. Kidney Dis. 67:6 (2016), 949–953, 10.1053/j.ajkd.2016.01.012 Epub 2016 Feb 17.
123. [123] Abrera-Abeleda, M.A., Nishimura, C., Frees, K., Jones, M., Maga, T., Katz, L.M., et al. Allelic variants of complement genes associated with dense deposit disease. J. Am. Soc. Nephrol. 22 (2011), 1551–1559.
124. [124] Abrera-Abeleda, M.A., Nishimura, C., Smith, J.L., Sethi, S., McRae, J.L., Murphy, B.F., et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J. Med. Genet. 43 (2006), 582–589.
125. [125] Fervenza, F.C., Smith, R.J., Sethi, S., Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis. Am. J. Kidney Dis. 60 (2012), 126–132.
126. [126] Gale, D.P., de Jorge, E.G., Cook, H.T., Martinez-Barricarte, R., Hadjisavvas, A., McLean, A.G., et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376 (2010), 794–801.
127. [127] Licht, C., Heinen, S., Jozsi, M., Loschmann, I., Saunders, R.E., Perkins, S.J., et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int. 70 (2006), 42–50.
128. [128] Sethi, S., Smith, R.J., Dillon, J.J., Fervenza, F.C., C3 glomerulonephritis associated with complement factor B mutation. Am. J. Kidney Dis. 65:3 (2015), 520–521, 10.1053/j.ajkd.2014.10.023.
129. [129] Malik, T.H., Lavin, P.J., Goicoechea de Jorge, E., Vernon, K.A., Rose, K.L., Patel, M.P., et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J. Am. Soc. Nephrol. 23 (2012), 1155–1160.
130. [130] Edwards, A.O., Ritter, R. 3rd., Abel, K.J., Manning, A., Panhuysen, C., Farrer, L.A., Complement factor H polymorphism and age-related macular degeneration. Science 308 (2005), 421–424.
131. [131] Hageman, G.S., Anderson, D.H., Johnson, L.V., Hancox, L.S., Taiber, A.J., Hardisty, L.I., et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 7227–7232.
132. [132] Haines, J.L., Hauser, M.A., Schmidt, S., Scott, W.K., Olson, L.M., Gallins, P., et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308 (2005), 419–421.
133. [133] McHarg, S., Clark, S.J., Day, A.J., Bishop, P.N., Age-related macular degeneration and the role of the complement system. Mol. Immunol. 67 (2015), 43–50.
134. [134] Schramm, E.C., Clark, S.J., Triebwasser, M.P., Raychaudhuri, S., Seddon, J.M., Atkinson, J.P., Genetic variants in the complement system predisposing to age-related macular degeneration: a review. Mol. Immunol. 61 (2014), 118–125.
135. [135] Ekdahl, K.N., Norberg, D., Bengtsson, A.A., Sturfelt, G., Nilsson, U.R., Nilsson, B., Use of serum or buffer-changed EDTA-plasma in a rapid, inexpensive, and easy-to-perform hemolytic complement assay for differential diagnosis of systemic lupus erythematosus and monitoring of patients with the disease. Clin. Vaccine Immunol. 14 (2007), 549–555.
136. [136] Stegert, M., Bock, M., Trendelenburg, M., Clinical presentation of human C1q deficiency: how much of a lupus?. Mol. Immunol. 67 (2015), 3–11.
137. [137] Walport, M.J., Davies, K.A., Botto, M., C1q and systemic lupus erythematosus. Immunobiology 199 (1998), 265–285.
138. [138] Taylor, P.R., Carugati, A., Fadok, V.A., Cook, H.T., Andrews, M., Carroll, M.C., et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J. Exp. Med. 192 (2000), 359–366.
139. [139] Moroni, G., Quaglini, S., Radice, A., Trezzi, B., Raffiotta, F., Messa, P., et al. The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy. J. Immunol. Res., 2015, 2015, 106904.
140. [140] Pons-Estel, G.J., Serrano, R., Plasin, M.A., Espinosa, G., Cervera, R., Epidemiology and management of refractory lupus nephritis. Autoimmun. Rev. 10 (2011), 655–663.
141. [141] Pickering, M.C., Botto, M., Taylor, P.R., Lachmann, P.J., Walport, M.J., Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv. Immunol. 76 (2000), 227–324.
142. [142] Vasilev, V.V., Noe, R., Dragon-Durey, M.A., Chauvet, S., Lazarov, V.J., Deliyska, B.P., et al. Functional characterization of autoantibodies against complement component C3 in patients with lupus nephritis. J. Biol. Chem. 290 (2015), 25343–25355.
143. [143] Gatto, M., Iaccarino, L., Ghirardello, A., Punzi, L., Doria, A., Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: a comprehensive review. J. Autoimmun. 69 (2016), 1–11.
144. [144] Pang, Y., Yang, X.W., Song, Y., Yu, F., Zhao, M.H., Anti-C1q autoantibodies from active lupus nephritis patients could inhibit the clearance of apoptotic cells and complement classical pathway activation mediated by C1q in vitro. Immunobiology 219 (2014), 980–989.
145. [145] Thanei, S., Vanhecke, D., Trendelenburg, M., Anti-C1q autoantibodies from systemic lupus erythematosus patients activate the complement system via both the classical and lectin pathways. Clin. Immunol. 160 (2015), 180–187.
146. [146] Ramos-Casals, M., Brito-Zeron, P., Soria, N., Nardi, N., Vargas, A., Munoz, S., et al. Mannose-binding lectin-low genotypes are associated with milder systemic and immunological disease expression in primary Sjogren's syndrome. Rheumatology (Oxford) 48 (2009), 65–69.
147. [147] Wen, W., Liu, Y., Zhao, C., Sun, X., Zhang, C., Li, Z., Clinical and serologic features of primary Sjogren's syndrome concomitant with autoimmune hemolytic anemia: a large-scale cross-sectional study. Clin. Rheumatol. 34 (2015), 1877–1884.
148. [148] Yang, Y., Li, Z., Wang, L., Zhang, F., The clinical and laboratory characteristics of Sjogren's syndrome that progresses to systemic lupus erythematosus: a retrospective case-control study. Int. J. Rheum. Dis. 16 (2013), 173–177.
149. [149] Zadura, A.F., Theander, E., Blom, A.M., Trouw, L.A., Complement inhibitor C4b-binding protein in primary Sjogren's syndrome and its association with other disease markers. Scand. J. Immunol. 69 (2009), 374–380.
150. [150] Du Clos, T.W., Mold, C., Complement in host deficiencies and diseases. Rich, R.R., (eds.) Clinical Immunology: Principles and Practice, fourth ed., 2013, Elsevier, Amsterdam, The Netherlands.
151. [151] Borzova, E., Grattan, C.E.H., Urticaria, angioedema, and anaphylaxis. Rich, R.R., (eds.) Clinical Immunology: Principles and Practice, fourth ed., 2013, Elsevier, Amsterdam, The Netherlands.
152. [152] Markowitz, G.S., D'Agati, V.D., Classification of lupus nephritis. Curr. Opin. Nephrol. Hypertens. 18 (2009), 220–225.
153. [153] Birmingham, D.J., Irshaid, F., Nagaraja, H.N., Zou, X., Tsao, B.P., Wu, H., et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 19 (2010), 1272–1280.
154. [154] Manzi, S., Navratil, J.S., Ruffing, M.J., Liu, C.C., Danchenko, N., Nilson, S.E., et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum. 50 (2004), 3596–3604.
155. [155] Korczowska, I., Rheumatoid arthritis susceptibility genes: an overview. World J. Orthop. 5 (2014), 544–549.
156. [156] Giles, J.L., Choy, E., van den Berg, C., Morgan, B.P., Harris, C.L., Response to comment on “Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis”. J. Immunol., 195, 2015, 4.
157. [157] Giles, J.L., Choy, E., van den Berg, C., Morgan, B.P., Harris, C.L., Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis. J. Immunol. 194 (2015), 3029–3034.
158. [158] Petri, C., Thiel, S., Jensenius, J.C., Herlin, T., Investigation of complement-activating pattern recognition molecules and associated enzymes as possible inflammatory markers in oligoarticular and systemic juvenile idiopathic arthritis. J. Rheumatol. 42 (2015), 1252–1258.
159. [159] Sethi, S., Fervenza, F.C., Membranoproliferative glomerulonephritis—a new look at an old entity. N. Engl. J. Med. 366 (2012), 1119–1131.
160. [160] Landgren, O., Kyle, R.A., Pfeiffer, R.M., Katzmann, J.A., Caporaso, N.E., Hayes, R.B., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113 (2009), 5412–5417.
161. [161] Tsai, H.T., Caporaso, N.E., Kyle, R.A., Katzmann, J.A., Dispenzieri, A., Hayes, R.B., et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood 114 (2009), 4928–4932.
162. [162] Weiss, B.M., Abadie, J., Verma, P., Howard, R.S., Kuehl, W.M., A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113 (2009), 5418–5422.
163. [163] Kyle, R.A., Rajkumar, S.V., Monoclonal gammopathy of undetermined significance. Br. J. Haematol. 134 (2006), 573–589.
164. [164] Siegel, R., Ma, J., Zou, Z., Jemal, A., Cancer statistics, 2014. CA Cancer J. Clin. 64 (2014), 9–29.
165. [165] Bridoux, F., Leung, N., Hutchison, C.A., Touchard, G., Sethi, S., Fermand, J.P., et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 87 (2015), 698–711.
166. [166] Leung, N., Bridoux, F., Hutchison, C.A., Nasr, S.H., Cockwell, P., Fermand, J.P., et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 120 (2012), 4292–4295.
167. [167] Brouet, J.C., Clauvel, J.P., Danon, F., Klein, M., Seligmann, M., Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am. J. Med. 57 (1974), 775–788.
168. [168] Zago-Novaretti, M., Khuri, F., Miller, K.B., Berkman, E.M., Waldenstrom's macroglobulinemia with an IgM paraprotein that is both a cold agglutinin and a cryoglobulin and has a suppressive effect on progenitor cell growth. Transfusion 34 (1994), 910–914.
169. [169] Wiltink, W.F., Esseveld, M.R., Gerbrandy, J., van Eijk, H.G., Hyperviscosity in cold environment caused by a 6.5 S cryoglobulin in a patient with rheumatoid arthritis. Acta Med. Scand. 193 (1973), 133–135.
170. [170] Dutcher, J.P., Therapeutic cytapheresis, plasmapheresis, and plasma exchange in neoplastic diseases of the blood. Neoplastic Diseases of the Blood, 2013, 1241–1249, Springer; New York.
171. [171] Gorevic, P.D., Kassab, H.J., Levo, Y., Kohn, R., Meltzer, M., Prose, P., et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am. J. Med. 69 (1980), 287–308.
172. [172] Gorevic, P.D., Rheumatoid factor, complement, and mixed cryoglobulinemia. Clin. Dev. Immunol., 2012, 2012, 439018.
173. [173] Ali, O.S., Abo-Shadi, M.A., Hammad, L.N., The biological significance of serum complements C3 and C4 in HCV-related chronic liver diseases and hepatocellular carcinoma. Egypt. J. Immunol. 12 (2005), 91–99.
174. [174] Mazumdar, B., Kim, H., Meyer, K., Bose, S.K., Di Bisceglie, A.M., Ray, R.B., et al. Hepatitis C virus proteins inhibit C3 complement production. J. Virol. 86 (2012), 2221–2228.
175. [175] Dumestre-Perard, C., Ponard, D., Drouet, C., Leroy, V., Zarski, J.P., Dutertre, N., et al. Complement C4 monitoring in the follow-up of chronic hepatitis C treatment. Clin. Exp. Immunol. 127 (2002), 131–136.
176. [176] Sansonno, D., Lauletta, G., Nisi, L., Gatti, P., Pesola, F., Pansini, N., et al. Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia. Clin. Exp. Immunol. 133 (2003), 275–282.
177. [177] Levo, Y., Hepatitis B, virus and essential mixed cryoglobulinemia. Ann. Intern. Med., 94, 1981, 282.
178. [178] Suarez, A., Vallina, E., Navascues, C.A., Rodriguez, M., Otero, L., Sotorrio, N.G., et al. Mixed type-II cryoglobulinemia associated with a chronic hepatitis C virus infection. Rev. Clin. Esp. 192 (1993), 325–326.
179. [179] Sethi, S., Fervenza, F.C., Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin. Nephrol. 31 (2011), 341–348.
180. [180] Pickering, M.C., D'Agati, V.D., Nester, C.M., Smith, R.J., Haas, M., Appel, G.B., et al. C3 glomerulopathy: consensus report. Kidney Int. 84 (2013), 1079–1089.
181. [181] Zipfel, P.F., Skerka, C., Chen, Q., Wiech, T., Goodship, T., Johnson, S., et al. The role of complement in C3 glomerulopathy. Mol. Immunol. 67 (2015), 21–30.
182. [182] Servais, A., Noel, L.H., Roumenina, L.T., Le Quintrec, M., Ngo, S., Dragon-Durey, M.A., et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 82 (2012), 454–464.
183. [183] Sethi, S., Fervenza, F.C., Zhang, Y., Zand, L., Vrana, J.A., Nasr, S.H., et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 82 (2012), 465–473.
184. [184] Daha, M.R., Van Es, L.A., Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor. Immunology 43 (1981), 33–38.
185. [185] Zhang, Y., Meyer, N.C., Wang, K., Nishimura, C., Frees, K., Jones, M., et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin. J. Am. Soc. Nephrol. 7 (2012), 265–274.
186. [186] Chen, Q., Muller, D., Rudolph, B., Hartmann, A., Kuwertz-Broking, E., Wu, K., et al. Combined C3b and factor B autoantibodies and MPGN type II. N. Engl. J. Med. 365 (2011), 2340–2342.
187. [187] Marinozzi, M.C., Roumenina, L., Chauvet, S., Dragon-Durey, M.A., Fremeaux-Bacchi, V., Le Quintrec, M., Prevalence and characteristics of anti-factor B and anti-C3 autoantibodies in a cohort of C3 glomerulopathy and membranoproliferative glomerulonephritis type I. Mol. Immunol., 67, 2015, 159.
188. [188] Sethi, S., Fervenza, F.C., Zhang, Y., Zand, L., Meyer, N.C., Borsa, N., et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int. 83 (2013), 293–299.
189. [189] Smith, R.J., Harris, C.L., Pickering, M.C., Dense deposit disease. Mol. Immunol. 48 (2011), 1604–1610.
190. [190] Sethi, S., Fervenza, F.C., Zhang, Y., Nasr, S.H., Leung, N., Vrana, J., et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin. J. Am. Soc. Nephrol. 6 (2011), 1009–1017.
191. [191] Coleman, A.L., Yu, F., Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999. Ophthalmology 115 (2008), 18–25.
192. [192] Kavanagh, D., Yu, Y., Schramm, E.C., Triebwasser, M., Wagner, E.K., Raychaudhuri, S., et al. Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels. Hum. Mol. Genet. 24 (2015), 3861–3870.
193. [193] Triebwasser, M.P., Roberson, E.D., Yu, Y., Schramm, E.C., Wagner, E.K., Raychaudhuri, S., et al. Rare variants in the functional domains of complement factor H are associated with age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 56 (2015), 6873–6878.
194. [194] Anderson, D.H., Mullins, R.F., Hageman, G.S., Johnson, L.V., A role for local inflammation in the formation of drusen in the aging eye. Am. J. Ophthalmol. 134 (2002), 411–431.
195. [195] Dalvin, L.A., Fervenza, F.C., Sethi, S., Pulido, J.S., Shedding light on fundus drusen associated with membranoproliferative glomerulonephritis: breaking stereotypes of types I, II, and III. Retin Cases Brief Rep. 10 (2016), 72–78.
196. [196] Ba, J., Peng, R.S., Xu, D., Li, Y.H., Shi, H., Wang, Q., et al. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Des. Devel. Ther. 9 (2015), 5397–5405.
197. [197] Dedania, V.S., Bakri, S.J., Sustained elevation of intraocular pressure after intravitreal anti-VEGF agents: what is the evidence?. Retina 35 (2015), 841–858.
198. [198] Hanus, J., Zhao, F., Wang, S., Current therapeutic development for atrophic age-related macular degeneration. Br. J. Ophthalmol. 100:1 (2016), 122–127, 10.1136/bjophthalmol-2015-306972 Epub 2015 Nov 9.
199. [199] Tolentino, M.J., Dennrick, A., John, E., Tolentino, M.S., Drugs in phase II clinical trials for the treatment of age-related macular degeneration. Expert Opin. Investig. Drugs 24 (2015), 183–199.
200. [200] Noris, M., Remuzzi, G., Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361 (2009), 1676–1687.
201. [201] Taylor, C.M., Machin, S., Wigmore, S.J., Goodship, T.H., Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br. J. Haematol. 148 (2010), 37–47.
202. [202] Fremeaux-Bacchi, V., Fakhouri, F., Garnier, A., Bienaime, F., Dragon-Durey, M.A., Ngo, S., et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin. J. Am. Soc. Nephrol. 8 (2013), 554–562.
203. [203] Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 5 (2010), 1844–1859.
204. [204] Kaplan, B.S., Meyers, K.E., Schulman, S.L., The pathogenesis and treatment of hemolytic uremic syndrome. J. Am. Soc. Nephrol. 9 (1998), 1126–1133.
205. [205] Besbas, N., Karpman, D., Landau, D., Loirat, C., Proesmans, W., Remuzzi, G., et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 70 (2006), 423–431.
206. [206] Kavanagh, D., Kemp, E.J., Mayland, E., Winney, R.J., Duffield, J.S., Warwick, G., et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16 (2005), 2150–2155.
207. [207] Fremeaux-Bacchi, V., Moulton, E.A., Kavanagh, D., Dragon-Durey, M.A., Blouin, J., Caudy, A., et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 17 (2006), 2017–2025.
208. [208] Rougier, N., Kazatchkine, M.D., Rougier, J.P., Fremeaux-Bacchi, V., Blouin, J., Deschenes, G., et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J. Am. Soc. Nephrol. 9 (1998), 2318–2326.
209. [209] Goicoechea de Jorge, E., Harris, C.L., Esparza-Gordillo, J., Carreras, L., Arranz, E.A., Garrido, C.A., et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 240–245.
210. [210] Caprioli, J., Noris, M., Brioschi, S., Pianetti, G., Castelletti, F., Bettinaglio, P., et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108 (2006), 1267–1279.
211. [211] Geerdink, L.M., Westra, D., van Wijk, J.A., Dorresteijn, E.M., Lilien, M.R., Davin, J.C., et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr. Nephrol. 27 (2012), 1283–1291.
212. [212] Bu, F., Maga, T., Meyer, N.C., Wang, K., Thomas, C.P., Nester, C.M., et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 25 (2014), 55–64.
213. [213] Moore, I., Strain, L., Pappworth, I., Kavanagh, D., Barlow, P.N., Herbert, A.P., et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115 (2010), 379–387.
214. [214] Jozsi, M., Licht, C., Strobel, S., Zipfel, S.L., Richter, H., Heinen, S., et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111 (2008), 1512–1514.
215. [215] Skerka, C., Jozsi, M., Zipfel, P.F., Dragon-Durey, M.A., Fremeaux-Bacchi, V., Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb. Haemost. 101 (2009), 227–232.
216. [216] Dragon-Durey, M.A., Loirat, C., Cloarec, S., Macher, M.A., Blouin, J., Nivet, H., et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16 (2005), 555–563.
217. [217] Sinha, A., Gulati, A., Saini, S., Blanc, C., Gupta, A., Gurjar, B.S., et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int. 85 (2014), 1151–1160.
218. [218] Hofer, J., Janecke, A.R., Zimmerhackl, L.B., Riedl, M., Rosales, A., Giner, T., et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 8 (2013), 407–415.
219. [219] Jozsi, M., Strobel, S., Dahse, H.M., Liu, W.S., Hoyer, P.F., Oppermann, M., et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 110 (2007), 1516–1518.
220. [220] Jozsi, M., Heinen, S., Hartmann, A., Ostrowicz, C.W., Halbich, S., Richter, H., et al. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J. Am. Soc. Nephrol. 17 (2006), 170–177.
221. [221] Lemaire, M., Fremeaux-Bacchi, V., Schaefer, F., Choi, M., Tang, W.H., Le Quintrec, M., et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat. Genet. 45 (2013), 531–536.
222. [222] Sellier-Leclerc, A.L., Fremeaux-Bacchi, V., Dragon-Durey, M.A., Macher, M.A., Niaudet, P., Guest, G., et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 18 (2007), 2392–2400.
223. [223] Bresin, E., Daina, E., Noris, M., Castelletti, F., Stefanov, R., Hill, P., et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin. J. Am. Soc. Nephrol. 1 (2006), 88–99.
224. [224] Loirat, C., Fremeaux-Bacchi, V., Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr. Transplant. 12 (2008), 619–629.
225. [225] Saland, J.M., Ruggenenti, P., Remuzzi, G., Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 20 (2009), 940–949.
226. [226] Larrea, C.F., Cofan, F., Oppenheimer, F., Campistol, J.M., Escolar, G., Lozano, M., Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 89 (2010), 903–904.
227. [227] Alachkar, N., Bagnasco, S.M., Montgomery, R.A., Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transpl. Int. 25 (2012), e93–e95.
228. [228] Zimmerhackl, L.B., Hofer, J., Cortina, G., Mark, W., Wurzner, R., Jungraithmayr, T.C., et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 362 (2010), 1746–1748.
229. [229] Weitz, M., Amon, O., Bassler, D., Koenigsrainer, A., Nadalin, S., Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr. Nephrol. 26 (2011), 1325–1329.
230. [230] Krid, S., Roumenina, L.T., Beury, D., Charbit, M., Boyer, O., Fremeaux-Bacchi, V., et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am. J. Transplant. 12 (2012), 1938–1944.
231. [231] Nester, C., Stewart, Z., Myers, D., Jetton, J., Nair, R., Reed, A., et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 6 (2011), 1488–1494.
232. [232] George, J.N., Nester, C.M., Syndromes of thrombotic microangiopathy. N. Engl. J. Med. 371 (2014), 654–666.
233. [233] Mannucci, P.M., Cugno, M., The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: laboratory weapons and their impact on treatment choice and monitoring. Thromb. Res. 136 (2015), 851–854.
234. [234] Novak, R.W., Martin, C.R., Orsini, E.N., Hemolytic-uremic syndrome and T-cryptantigen exposure by neuraminidase-producing pneumococci: an emerging problem?. Pediatr. Pathol. 1 (1983), 409–413.
235. [235] Kavanagh, D., Goodship, T.H., Richards, A., Atypical haemolytic uraemic syndrome. Br. Med. Bull. 77 (2006), 5–22.
236. [236] Ariceta, G., Besbas, N., Johnson, S., Karpman, D., Landau, D., Licht, C., et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr. Nephrol. 24 (2009), 687–696.
237. [237] Tsai, M.R., Cheng, Y.H., Chen, J.S., Sheen, Y.S., Liao, Y.H., Sun, C.K., Differential diagnosis of nonmelanoma pigmented skin lesions based on harmonic generation microscopy. J. Biomed. Opt., 19, 2014, 36001.
238. [238] Robson, W.L., Leung, A.K., Fick, G.H., McKenna, A.I., Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron 62 (1992), 296–299.
239. [239] Lapeyraque, A.L., Malina, M., Fremeaux-Bacchi, V., Boppel, T., Kirschfink, M., Oualha, M., et al. Eculizumab in severe Shiga-toxin-associated HUS. N. Engl. J. Med. 364 (2011), 2561–2563.
240. [240] Ruiz-Torres, M.P., Casiraghi, F., Galbusera, M., Macconi, D., Gastoldi, S., Todeschini, M., et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb. Haemost. 93 (2005), 443–452.
241. [241] Noris, M., Galbusera, M., Gastoldi, S., Macor, P., Banterla, F., Bresin, E., et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124 (2014), 1715–1726.
242. [242] Thurman, J.M., Marians, R., Emlen, W., Wood, S., Smith, C., Akana, H., et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 4 (2009), 1920–1924.
243. [243] Reti, M., Farkas, P., Csuka, D., Razso, K., Schlammadinger, A., Udvardy, M.L., et al. Complement activation in thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 10 (2012), 791–798.
244. [244] Kwon, T., Dragon-Durey, M.A., Macher, M.A., Baudouin, V., Maisin, A., Peuchmaur, M., et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol. Dial. Transplant. 23 (2008), 2088–2090.
245. [245] Dragon-Durey, M.A., Fremeaux-Bacchi, V., Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin. Immunopathol. 27 (2005), 359–374.
246. [246] Gulbis, B., Eleftheriou, A., Angastiniotis, M., Ball, S., Surralles, J., Castella, M., et al. Epidemiology of rare anaemias in Europe. Adv. Exp. Med. Biol. 686 (2010), 375–396.
247. [247] Borowitz, M.J., Craig, F.E., Digiuseppe, J.A., Illingworth, A.J., Rosse, W., Sutherland, D.R., et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin. Cytom. 78 (2010), 211–230.
248. [248] Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73 (1993), 703–711.
249. [249] Holguin, M.H., Wilcox, L.A., Bernshaw, N.J., Rosse, W.F., Parker, C.J., Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 84 (1989), 1387–1394.
250. [250] Motoyama, O., Ohshima, M., Shigetomi, Y., Ohara, T., Nagai, Y., Kawamura, S., et al. Hereditary nephritis associated with low-tone sensorineural hearing difficulty: a case report. Nihon Jinzo Gakkai Shi. 38 (1996), 233–237.
251. [251] Yamashina, M., Ueda, E., Kinoshita, T., Takami, T., Ojima, A., Ono, H., et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 323 (1990), 1184–1189.
252. [252] Rollins, S.A., Sims, P.J., The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J. Immunol. 144 (1990), 3478–3483.
253. [253] Hillmen, P., Muus, P., Roth, A., Elebute, M.O., Risitano, A.M., Schrezenmeier, H., et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 162 (2013), 62–73.
254. [254] Rother, R.P., Rollins, S.A., Mojcik, C.F., Brodsky, R.A., Bell, L., Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25 (2007), 1256–1264.
255. [255] Hillmen, P., Lewis, S.M., Bessler, M., Luzzatto, L., Dacie, J.V., Natural history of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 333 (1995), 1253–1258.
256. [256] Socie, G., Mary, J.Y., de Gramont, A., Rio, B., Leporrier, M., Rose, C., et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 348 (1996), 573–577.
257. [257] Hall, S.E., Rosse, W.F., The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood 87 (1996), 5332–5340.
258. [258] Parker, C., Omine, M., Richards, S., Nishimura, J., Bessler, M., Ware, R., et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106 (2005), 3699–3709.
259. [259] Bowen, T., Cicardi, M., Farkas, H., Bork, K., Longhurst, H.J., Zuraw, B., et al. International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin. Immunol., 6, 2010, 24.
260. [260] Cicardi, M., Bork, K., Caballero, T., Craig, T., Li, H.H., Longhurst, H., et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 67 (2012), 147–157.
261. [261] Craig, T., Aygoren-Pursun, E., Bork, K., Bowen, T., Boysen, H., Farkas, H., et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ. J. 5 (2012), 182–199.
262. [262] Longhurst, C., Give UK, nursing bigger global voice by rejoining ICN, college is urged. Nurs. Stand., 29, 2015, 8.
263. [263] Zanichelli, A., Wu, M.A., Andreoli, A., Mansi, M., Cicardi, M., The safety of treatments for angioedema with hereditary C1 inhibitor deficiency. Expert Opin. Drug Saf. 14:11 (2015), 1725–1736, 10.1517/14740338.2015.1094053.
264. [264] Craig, T.J., Levy, R.J., Wasserman, R.L., Bewtra, A.K., Hurewitz, D., Obtulowicz, K., et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J. Allergy Clin. Immunol. 124 (2009), 801–808.
265. [265] Bork, K., Meng, G., Staubach, P., Hardt, J., Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45 (2005), 1774–1784.
266. [266] Farkas, H., Jakab, L., Temesszentandrasi, G., Visy, B., Harmat, G., Fust, G., et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J. Allergy Clin. Immunol. 120 (2007), 941–947.
267. [267] Bork, K., Staubach, P., Hardt, J., Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy 63 (2008), 751–757.
268. [268] Zuraw, B.L., Busse, P.J., White, M., Jacobs, J., Lumry, W., Baker, J., et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N. Engl. J. Med. 363 (2010), 513–522.
269. [269] Lumry, W., Manning, M.E., Hurewitz, D.S., Davis-Lorton, M., Fitts, D., Kalfus, I.N., et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. J. Pediatr. 162 (2013), 1017–1022 e1–2.
270. [270] Cicardi, M., Mannucci, P.M., Castelli, R., Rumi, M.G., Agostoni, A., Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion 35 (1995), 209–212.
271. [271] Zuraw, B., Cicardi, M., Levy, R.J., Nuijens, J.H., Relan, A., Visscher, S., et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J. Allergy Clin. Immunol. 126 (2010), 821–827 e14.
272. [272] Riedl, M.A., Levy, R.J., Suez, D., Lockey, R.F., Baker, J.W., Relan, A., et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann. Allergy Asthma Immunol. 110 (2013), 295–299.
273. [273] Riedl, M.A., Bernstein, J.A., Li, H., Reshef, A., Lumry, W., Moldovan, D., et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann. Allergy Asthma Immunol. 112 (2014), 163–169 e1.
274. [274] Martinez-Saguer, I., Rusicke, E., Aygoren-Pursun, E., von Hentig, N., Klingebiel, T., Kreuz, W., Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion 50 (2010), 354–360.
275. [275] Cicardi, M., Levy, R.J., McNeil, D.L., Li, H.H., Sheffer, A.L., Campion, M., et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N. Engl. J. Med. 363 (2010), 523–531.
276. [276] Levy, R.J., Lumry, W.R., McNeil, D.L., Li, H.H., Campion, M., Horn, P.T., et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann. Allergy Asthma Immunol. 104 (2010), 523–529.
277. [277] Sheffer, A.L., MacGinnitie, A.J., Campion, M., Stolz, L.E., Pullman, W.E., Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Ann. Allergy Asthma Immunol. 110 (2013), 184–188 e2.
278. [278] MacGinnitie, A.J., Davis-Lorton, M., Stolz, L.E., Tachdjian, R., Use of ecallantide in pediatric hereditary angioedema. Pediatrics 132 (2013), e490–e497.
279. [279] Cicardi, M., Banerji, A., Bracho, F., Malbran, A., Rosenkranz, B., Riedl, M., et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N. Engl. J. Med. 363 (2010), 532–541.
280. [280] Lumry, W.R., Li, H.H., Levy, R.J., Potter, P.C., Farkas, H., Moldovan, D., et al. Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann. Allergy Asthma Immunol. 107 (2011), 529–537.
281. [281] Maurer, M., Aberer, W., Bouillet, L., Caballero, T., Fabien, V., Kanny, G., et al. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One, 8, 2013, e53773.
282. [282] Bygum, A., Hereditary angioedema—consequences of a new treatment paradigm in Denmark. Acta Derm. Venereol. 94 (2014), 436–441.
283. [283] Bork, K., An evidence based therapeutic approach to hereditary and acquired angioedema. Curr. Opin. Allergy Clin. Immunol. 14 (2014), 354–362.
284. [284] Rizk, C., Karsh, J., Santucci, S., Yang, W., Self-administration of intravenous C1 esterase inhibitor in hereditary angioedema. CMAJ 185 (2013), 791–792.
285. [285] Tourangeau, L.M., Castaldo, A.J., Davis, D.K., Koziol, J., Christiansen, S.C., Zuraw, B.L., Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy. Int. Arch. Allergy Immunol. 157 (2012), 417–424.
286. [286] Aberer, W., Maurer, M., Reshef, A., Longhurst, H., Kivity, S., Bygum, A., et al. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Allergy 69 (2014), 305–314.
287. [287] Bork, K., Bygum, A., Hardt, J., Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann. Allergy Asthma Immunol. 100 (2008), 153–161.
288. [288] Bernstein, J.A., Manning, M.E., Li, H., White, M.V., Baker, J., Lumry, W.R., et al. Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema. J. Allergy Clin. Immunol. Pract. 2 (2014), 77–84.
289. [289] Longhurst, H.J., Tarzi, M.D., Ashworth, F., Bethune, C., Cale, C., Dempster, J., et al. C1 inhibitor deficiency: 2014 United Kingdom consensus document. Clin. Exp. Immunol. 180 (2015), 475–483.
290. [290] Alsenz, J., Lambris, J.D., Bork, K., Loos, M., Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients’ C1-INH and anti-C1-INH autoantibodies. J. Clin. Invest. 83 (1989), 1794–1799.
291. [291] Bork, K., Witzke, G., Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J. Allergy Clin. Immunol. 83 (1989), 677–682.
292. [292] Levi, M., Hack, C.E., van Oers, M.H., Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. Am. J. Med. 119 (2006), e3–e5.
293. [293] Bright, P., Dempster, J., Longhurst, H., Successful treatment of acquired C1 inhibitor deficiency with icatibant. Clin. Exp. Dermatol. 35 (2010), 553–554.
294. [294] Patel, N.S., Fung, S.M., Zanichelli, A., Cicardi, M., Cohn, J.R., Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency. Allergy Asthma Proc. 34 (2013), 72–77.
295. [295] Weller, K., Magerl, M., Maurer, M., Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. J. Eur. Acad. Dermatol. Venereol. 25 (2011), 119–120.
296. [296] Zanichelli, A., Bova, M., Coerezza, A., Petraroli, A., Triggiani, M., Cicardi, M., Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study. Allergy 67 (2012), 1074–1077.
297. [297] Thomas, T.C., Rollins, S.A., Rother, R.P., Giannoni, M.A., Hartman, S.L., Elliott, E.A., et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33 (1996), 1389–1401.
298. [298] Reis, E.S., Mastellos, D.C., Yancopoulou, D., Risitano, A.M., Ricklin, D., Lambris, J.D., Applying complement therapeutics to rare diseases. Clin. Immunol. 161 (2015), 225–240.
299. [299] Legendre, C.M., Licht, C., Muus, P., Greenbaum, L.A., Babu, S., Bedrosian, C., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368 (2013), 2169–2181.
300. [300] Licht, C., Greenbaum, L.A., Muus, P., Babu, S., Bedrosian, C.L., Cohen, D.J., et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 87 (2015), 1061–1073.
301. [301] Rathbone, J., Kaltenthaler, E., Richards, A., Tappenden, P., Bessey, A., Cantrell, A., A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open, 3, 2013, e003573.
302. [302] Zuber, J., Le Quintrec, M., Krid, S., Bertoye, C., Gueutin, V., Lahoche, A., et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am. J. Transplant. 12 (2012), 3337–3354.
303. [303] Hillmen, P., Hall, C., Marsh, J.C., Elebute, M., Bombara, M.P., Petro, B.E., et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 350 (2004), 552–559.
304. [304] Hillmen, P., Young, N.S., Schubert, J., Brodsky, R.A., Socie, G., Muus, P., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355 (2006), 1233–1243.
305. [305] Brodsky, R.A., Young, N.S., Antonioli, E., Risitano, A.M., Schrezenmeier, H., Schubert, J., et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111 (2008), 1840–1847.
306. [306] Hillmen, P., Muus, P., Duhrsen, U., Risitano, A.M., Schubert, J., Luzzatto, L., et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110 (2007), 4123–4128.
307. [307] Kelly, R.J., Hill, A., Arnold, L.M., Brooksbank, G.L., Richards, S.J., Cullen, M., et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117 (2011), 6786–6792.
308. [308] Nishimura, J., Yamamoto, M., Hayashi, S., Ohyashiki, K., Ando, K., Brodsky, A.L., et al. Genetic variants in C5 and poor response to eculizumab. N. Engl. J. Med. 370 (2014), 632–639.
309. [309] Rondelli, T., Risitano, A.M., Peffault de Latour, R., Sica, M., Peruzzi, B., Ricci, P., et al. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica 99 (2014), 262–266.
310. [310] Peffault de Latour, R., Fremeaux-Bacchi, V., Porcher, R., Xhaard, A., Rosain, J., Castaneda, D.C., et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 125 (2015), 775–783.
311. [311] Volokhina, E.B., van de Kar, N.C., Bergseth, G., van der Velden, T.J., Westra, D., Wetzels, J.F., et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin. Immunol. 160:2 (2015), 237–243, 10.1016/j.clim.2015.05.018 Epub 2015 Jun 23.
312. [312] Andreguetto, B., Murray, D., Snyder, M., Tostrud, L., Willrich, M.A., The impact of eculizumab in complement assays. Mol. Immunol. 67 (2015), 119–120.
313. [313] Ricklin, D., Lambris, J.D., Progress and trends in complement therapeutics. Adv. Exp. Med. Biol. 735 (2013), 1–22.